Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.

Investigational new drugs - 1 Oct 2018

Liu Songlin, Tang Yunhong, Yan Maomao, Jiang Weixi

Abstract excerpt

Breast cancer has been emerging as a most common threat among women, thus many efforts were made to find drugs for fighting breast cancer. So far, PI3K (Phosphatidylinositol-4,5-bisphosphate 3-kinase) inhibitors have been believed to be effective drugs until frequent resistance emerged. Recently, PI3K H1047R mutation has been reported to sensitize breast cancer cells to PI3K inhibition by aspirin. Considering...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoimidazole Carboxamide
Share to AMP-Activated Protein Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Drug Synergism

Share to Indazoles

Share to Mice, Nude

Share to Ribonucleotides

Share to Sulfonamides

Source

Identifiers

PMID: 29504069
DOI: 10.1007/s10637-018-0563-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.PMID 29504069Read ↗

Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.Semantic proximity Read ↗

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.Semantic proximity Read ↗

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.Semantic proximity Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

Differential crosstalk between the AMPK and PI3K/Akt pathways in breast cancer cells of differing genotypes: Leptin inhibits the effectiveness of AMPK activation.Semantic proximity Read ↗

Synergistic effects of inhibitors targeting PI3K and Aurora Kinase A in preclinical inflammatory breast cancer modelsSemantic proximity Read ↗

Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.Semantic proximity Read ↗

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.Semantic proximity Read ↗

Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.Semantic proximity Read ↗

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathwaySemantic proximity Read ↗

Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.Semantic proximity Read ↗

Mutations in PIK3CA Sensitize Breast Cancer Cells to Physiologic Levels of Aspirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.